Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 July 2020Website:
http://www.poseida.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 60 min agoDividend
Analysts recommendations
Institutional Ownership
PSTX Latest News
SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 7:55am PT | 10:55am ET.
SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Monday, June 17, 2024 at 1:00 p.m. PT. The Annual Meeting will be held through a live webcast.
Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024. The global multiple myeloma market size is projected to reach $31 billion by 2026. Allogenic off-the-shelf CAR-T technology has already garnered strategic investment interest from Astellas and a collaboration agreement with Roche.
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.39 per share a year ago.
Poseida Therapeutics is an oncology-focused biotech specializing in the development of cell therapies, particularly CAR T-cell approaches for multiple myeloma and acute leukemia. They have demonstrated promising early results in their clinical trials, with high response rates and manageable side effects. Particularly with respect to GvHD. The company also has gene therapy programs in development and has strong financial reserves to continue operations for several more quarters.
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.69 per share a year ago.
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.93 per share a year ago.
What type of business is Poseida Therapeutics?
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
What sector is Poseida Therapeutics in?
Poseida Therapeutics is in the Healthcare sector
What industry is Poseida Therapeutics in?
Poseida Therapeutics is in the Biotechnology industry
What country is Poseida Therapeutics from?
Poseida Therapeutics is headquartered in United States
When did Poseida Therapeutics go public?
Poseida Therapeutics initial public offering (IPO) was on 10 July 2020
What is Poseida Therapeutics website?
https://www.poseida.com
Is Poseida Therapeutics in the S&P 500?
No, Poseida Therapeutics is not included in the S&P 500 index
Is Poseida Therapeutics in the NASDAQ 100?
No, Poseida Therapeutics is not included in the NASDAQ 100 index
Is Poseida Therapeutics in the Dow Jones?
No, Poseida Therapeutics is not included in the Dow Jones index
When does Poseida Therapeutics report earnings?
The next expected earnings date for Poseida Therapeutics is 08 August 2024